Press Release

ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer

Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend

ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting

AVILAR THERAPEUTICS TO PRESENT NEW DATA FOR ATAC EXTRACELLULAR PROTEIN DEGRADERS AT TARGETED PROTEIN DEGRADATION SUMMIT

FDA Grants Fast Track Designation to ANPD001, Autologous Investigational Cell Therapy for the Treatment of Parkinson’s Disease

Nobias Therapeutics Announces Acceptance of Late-Breaking Abstract and Presentation of Phase 2 Clinical Data for NB-001 at 52nd Child Neurology Society Annual Meeting

AVILAR THERAPEUTICS TO PRESENT AT UPCOMING INDUSTRY CONFERENCES